Senior Analytical Chemist I, Metabolomics

Our mission is to make biology easier to engineer. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe’s growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms.

We are seeking a metabolomics scientist who will be a key contributor in the area of Natural Product Chemistry in the Chemistry group and provide expertise in the area of Metabolomics and Mass Spectrometry based structure elucidation. This position focuses on acquiring and analyzing metabolomics data from microbial samples, including developing novel methods and workflows and assisting in the development of computational pipelines for data analysis. #LI-LS1

Total compensation for this role is market driven, with a starting salary of $100,000 +, as well as company stock awards. Base pay is ultimately determined based on a candidate's skills, expertise, and experience. We also offer a comprehensive benefits package including medical, dental & vision coverage, health spending accounts, voluntary benefits, leave of absence policies, Employee Assistance Program, 401(k) program with employer contribution, 8 paid holidays in addition to a full-week winter shutdown and unlimited Paid Time Off policy.

To learn more about Ginkgo, visit www.ginkgobioworks.com/press/ or check out some curated press below:

What is it really like to take your company public via a SPAC? One Boston biotech shares its journey (Fortune)

Ginkgo Bioworks resizes the definition of going big in biotech, raising $2.5B in a record SPAC deal that weighs in with a whopping $15B-plus valuation (Endpoints News)

Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ (CNBC)

Ginkgo raises $70 million to ramp up COVID-19 testing for employers, universities (Boston Globe)

Ginkgo Bioworks Redirects Its Biotech Platform to Coronavirus (Wall Street Journal)

Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response (PRNewswire)

The Life Factory: Synthetic Organisms From This $1.4 Billion Startup Will Revolutionize Manufacturing (Forbes)

Synthetic Bio Pioneer Ginkgo Raises $290 Million in New Funding (Bloomberg)

Ginkgo Bioworks raises $350 million fund for biotech spinouts (Reuters)

Can This Company Convince You to Love GMOs? (The Atlantic)

We also feel that it’s important to point out the obvious here – there’s a serious lack of diversity in our industry, and that needs to change. Our goal is to help drive that change. Ginkgo is deeply committed to diversity, equity, and inclusion in all of its practices, especially when it comes to growing our team. Our culture promotes inclusion and embraces how rewarding it is to work with people from all walks of life.

We’re developing a powerful biological engineering platform, so we must remain mindful of the many ways our technology can – and will – impact people around the world. We care about how our platform is used, and having a diverse team to build it gives us the best chance that it’s something we’ll be proud of as it continues to grow. Therefore, it’s critical that we incorporate the diverse voices and visions of all those who play a role in the future of biology.

It is the policy of Ginkgo Bioworks to provide equal employment opportunities to all employees and employment applicants.